Nkarta, Inc. $NKTX Stock Holdings Increased by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. lifted its position in Nkarta, Inc. (NASDAQ:NKTX) by 18.0% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 147,551 shares of the company’s stock after acquiring an additional 22,538 shares during the period. Charles Schwab Investment Management Inc. owned about 0.21% of Nkarta worth $271,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Wealth Enhancement Advisory Services LLC purchased a new position in shares of Nkarta in the first quarter worth approximately $32,000. ProShare Advisors LLC purchased a new position in shares of Nkarta in the fourth quarter worth approximately $45,000. CWM LLC increased its position in shares of Nkarta by 3,437.3% in the first quarter. CWM LLC now owns 28,157 shares of the company’s stock worth $52,000 after acquiring an additional 27,361 shares in the last quarter. Cerity Partners LLC purchased a new position in shares of Nkarta in the first quarter worth approximately $55,000. Finally, Price T Rowe Associates Inc. MD increased its position in shares of Nkarta by 41.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 23,958 shares of the company’s stock worth $60,000 after acquiring an additional 7,030 shares in the last quarter. 80.54% of the stock is owned by hedge funds and other institutional investors.

Nkarta Stock Up 1.4%

NKTX stock opened at $2.13 on Friday. The company has a market capitalization of $151.29 million, a price-to-earnings ratio of -1.44 and a beta of 0.76. Nkarta, Inc. has a 12 month low of $1.31 and a 12 month high of $6.63. The firm has a 50 day moving average of $2.04 and a two-hundred day moving average of $1.89.

Nkarta (NASDAQ:NKTX) last posted its earnings results on Tuesday, August 12th. The company reported ($0.31) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.06. On average, research analysts expect that Nkarta, Inc. will post -1.7 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on NKTX. Needham & Company LLC reissued a “buy” rating and issued a $10.00 target price on shares of Nkarta in a research report on Wednesday, August 13th. Mizuho dropped their target price on Nkarta from $16.00 to $14.00 and set an “outperform” rating on the stock in a report on Tuesday, June 10th. William Blair reaffirmed a “market perform” rating on shares of Nkarta in a research report on Thursday, May 15th. Wall Street Zen raised shares of Nkarta from a “sell” rating to a “hold” rating in a research report on Saturday, August 16th. Finally, Stifel Nicolaus lowered their price objective on shares of Nkarta from $14.00 to $12.00 and set a “buy” rating on the stock in a research report on Thursday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $13.60.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.